BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18032975)

  • 1. New and old treatment modalities in primary myelofibrosis.
    Cervantes F; Mesa R; Barosi G
    Cancer J; 2007; 13(6):377-83. PubMed ID: 18032975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern management of myelofibrosis.
    Cervantes F
    Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
    Tefferi A
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
    Mesa RA
    Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients.
    Siragusa S; Passamonti F; Cervantes F; Tefferi A
    Am J Hematol; 2009 Mar; 84(3):140-3. PubMed ID: 19123461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches in the treatment of myelofibrosis.
    Hennessy BT; Thomas DA; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2005 Jan; 103(1):32-43. PubMed ID: 15565565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the therapy of chronic idiopathic myelofibrosis.
    Arana-Yi C; Quintás-Cardama A; Giles F; Thomas D; Carrasco-Yalan A; Cortes J; Kantarjian H; Verstovsek S
    Oncologist; 2006 Sep; 11(8):929-43. PubMed ID: 16951397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide for the treatment of idiopathic myelofibrosis.
    Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
    Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation as treatment for myelofibrosis.
    Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
    Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choosing between stem cell therapy and drugs in myelofibrosis.
    Kröger N; Mesa RA
    Leukemia; 2008 Mar; 22(3):474-86. PubMed ID: 18185525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic myelofibrosis: pathogenesis to treatment.
    Reilly JT
    Hematol Oncol; 2006 Jun; 24(2):56-63. PubMed ID: 16477581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation for myelofibrosis.
    van Besien K; Deeg HJ
    Semin Oncol; 2005 Aug; 32(4):414-21. PubMed ID: 16202687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic myelofibrosis.
    Barosi G; Hoffman R
    Semin Hematol; 2005 Oct; 42(4):248-58. PubMed ID: 16210038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic options for patients with myelofibrosis in blast phase.
    Mascarenhas J; Navada S; Malone A; Rodriguez A; Najfeld V; Hoffman R
    Leuk Res; 2010 Sep; 34(9):1246-9. PubMed ID: 20627294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology and treatment of primary myelofibrosis.
    Hoffman R; Rondelli D
    Hematology Am Soc Hematol Educ Program; 2007; ():346-54. PubMed ID: 18024650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
    Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
    Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide and lenalidomide in primary myelofibrosis.
    Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
    Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second allogeneic stem cell transplantation in myeloid malignancies.
    Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
    Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.